SCHEMBL23950686

SCHEMBL23950686

CC(=O)NCC(C)n1cnc2c(-c3cccnc3)nc(-c3ccc(C(F)(F)F)cc3)cc2c1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 2/20 0.40
SCD O00767 3/20 0.39
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
XBP1 P17861 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MC4R P32245 1/20 0.36
NTRK1 P04629 1/20 0.36
AHR P35869 1/20 0.35
HCRTR1 O43613 1/20 0.35
HCRTR2 O43614 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
TSPO P30536 1/20 0.34
PIM1 P11309 1/20 0.34
VHL P40337 1/20 0.34
KDR P35968 1/20 0.34
PTGS1 P23219 1/20 0.34
PTGS2 P35354 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23951122 0.90 EGLN1 (0.38) EGLN1SCDLMNAMAPTXBP1
SCHEMBL23950771 0.90 SCD (0.37) EGLN1SCDMAPTVHLDYRK1A
SCHEMBL23390257 0.89 EGLN1 (0.40) EGLN1LMNAMAPTXBP1SMN1; SMN2
SCHEMBL30101937 0.89 EGLN1 (0.40) EGLN1LMNAMAPTXBP1SMN1; SMN2
SCHEMBL23390259 0.89 EGLN1 (0.40) EGLN1LMNAMAPTXBP1SMN1; SMN2
SCHEMBL23950999 0.87 PIM1 (0.37) EGLN1SCDLMNAMAPTXBP1
SCHEMBL23925697 0.85 USP5 (0.40) EGLN1LMNAMAPTXBP1SMN1; SMN2
SCHEMBL23925568 0.85 ATR (0.41) DYRK1A
SCHEMBL23950645 0.84 EGLN1 (0.39) EGLN1SCDLMNAMAPTXBP1
SCHEMBL23925586 0.83 EGLN1 (0.39) EGLN1SCDLMNAMAPTXBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115443276-B Pyridopyrimidinone derivatives and their use as arene receptor modulators 东亚ST株式会社 2025-04-18 CN claimed
CN-115443276-B Pyridopyrimidinone derivatives and their use as arene receptor modulators 东亚ST株式会社 2025-04-18 CN disclosed
US-20230147257-A1 PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS DONG-A ST CO., LTD. (KR) 2023-05-11 US disclosed
CN-115443276-A Pyridopyrimidinone derivatives and their use as modulators of aromatic hydrocarbon receptors 东亚ST株式会社 2022-12-06 CN disclosed
WO-2021210970-A1 PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS DONG-A ST CO., LTD. (KR) 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230147257-A1 PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS AHR, ARNT, AIPL1 EGLN1 201/4885SCD 1395/4885LMNA 3455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.